US signs $1.5B deal for 100 million doses of Moderna’s coronavirus vaccine candidate

” Todays financial investment represents the next action in supporting this vaccine prospect all the method from early advancement by Moderna and the National Institutes of Health, through medical trials, and now massive manufacturing, with the potential to bring hundreds of countless safe and reliable doses to the American individuals,” HHS Secretary Alex Azar specified in a press release.

The vaccine prospect, mRNA-1273, will be made while its medical trials are underway. Moderna is developing the vaccine with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

The U.S. federal government inked an arrangement valued at up to $1.525 billion with Moderna Aug. 11 for 100 million dosages of its COVID-19 vaccine prospect.

More articles on drug store: CVS HealthHub rollout resumesMerck bets on one-shot vaccineVirginia drug store school files suit versus accreditation company, calls procedure bizarrely inconsistent and Kafkaesque.

Katie Adams –
Wednesday, August 12th, 2020
Print|Email.

By protecting the 100 million dosages, the federal government is scaling up its vaccine portfolio for Operation Warp Speed, the White House job force to speed shipment of a safe and reliable vaccine. The U.S. has the alternative to purchase 400 million more doses from Moderna.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.